Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Besançon – page 30

479 clinical trials in Besançon, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Besançon at a glance
479
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

479 trials in Besançon

Open in trial search

Colorectal cancer metastatic

Not recruiting

Study on Napabucasin with FOLFIRI for Adults with Metastatic Colorectal Cancer After Standard Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:1globe Health Institute LLC

Acute myeloid leukaemia+1

Not recruiting

Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enasidenib Mesilate
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Immune thrombocytopenia

Not recruiting

Study comparing dexamethasone versus immunoglobulin plus prednisone for adults with immune thrombocytopenia (ITP) who have moderate to severe bleeding

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Assistance Publique Hopitaux De Paris

Microsatellite instability cancer

Not recruiting

Study of Monalizumab and Volrustomig for Patients with MSI and/or dMMR Metastatic Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Monalizumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Major depression+1

Not recruiting

Study on Aticaprant and Antidepressant for Preventing Relapse in Adults with Major Depressive Disorder and Anhedonia

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Squamous cell carcinoma of skin

Not recruiting

Study of Cemiplimab Alone and with RP1 for Patients with Advanced Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Replimune Group Inc.

Cardiac failure

Not recruiting

Study on Dapagliflozin for Heart Failure Patients After a Heart Attack

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Assistance Publique Hopitaux De Paris

Hormone-refractory prostate cancer

Not recruiting

Study on the Safety and Effects of PT-112 for Patients with Advanced Prostate Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Imifoplatin
  • Sponsor:Promontory Therapeutics Inc.

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Renal cell carcinoma

Not recruiting

Study of Nivolumab and Ipilimumab for Patients with Advanced Kidney Cancer and Intermediate or Poor Risk Factors

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Ovarian epithelial cancer

Not recruiting

Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Besançon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on multiple myeloma, colorectal cancer, and melanoma treatments. Studies evaluate novel therapeutic combinations and maintenance strategies.

  • Advanced cancer therapies
  • Immunotherapy approaches
  • Targeted treatments

Several trials are exploring breakthrough treatments for various types of carcinomas and investigating new therapeutic pathways.

02 Neurological Disorders

Research focusing on multiple sclerosis and essential tremor. Studies evaluate treatment de-escalation strategies and novel therapeutic compounds.

  • Disease modification
  • Symptom management
  • Long-term outcomes

Trials aim to improve quality of life and develop more effective treatment approaches for neurological conditions.

03 Cardiovascular Studies

Investigations into heart failure prevention and treatments for elderly patients with coronary conditions. Studies examine innovative drug combinations and antiplatelet therapy strategies.

  • Preventive interventions
  • Therapeutic combinations
  • Elderly patient care

Research focuses on improving cardiovascular outcomes and developing targeted preventive strategies.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.